Focalin is used in the treatment of attention deficit hyperactivity disorder (ADHD).
Intellipharmaceutics will receive a cash amount from Par and will continue to obtain a share of profits from future sales, as per the agreement.
Intellipharmaceutics has a pending abbreviated new drug application (ANDA) with the FDA for five strengths (5, 10, 15, 20 and 30mg) of generic Focalin XR .
Intellipharmaceutics developes generic controlled-release and targeted-release oral solid dosage drugs with its patented Hypermatrix technology, a multidimensional controlled-release drug delivery platform.